C-ERBB-2 EXPRESSION IN DIFFERENT HISTOLOGICAL TYPES OF INVASIVE BREAST-CARCINOMA

被引:62
作者
SOOMRO, S
SHOUSHA, S
TAYLOR, P
SHEPARD, HM
FELDMANN, M
机构
[1] CHARING CROSS & WESTMINSTER MED SCH,DEPT HISTOPATHOL,LONDON W6 8RF,ENGLAND
[2] CHARING CROSS SUNLEY MED RES CTR,LONDON,ENGLAND
[3] GENENTECH INC,SAN FRANCISCO,CA 94080
关键词
D O I
10.1136/jcp.44.3.211
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Sections of 149 breast carcinomas were examined for the over-expression of c-erbB-2 oncoprotein using the avidinbiotin immunoperoxidase technique and two different specific antibodies. These included the polyclonal antibody 21N and the monoclonal antibody 4D5. The tumours were divided into two main groups. The first included 75 cases of invasive ductal and classic invasive lobular carcinomas. The second group consisted of 74 cases with histological types known to have a good prognosis, including mucinous, alveolar variant of invasive lobular, medullary, tubular, cribriform and papillary carcinomas. Fifteen (20%) tumours of the first group were positive with the two antibodies. Fourteen of these were of the ductal type and one was a mixed invasive ductal and lobular carcinoma. Ten of the pure ductal cases had areas of comedo carcinoma. The intraductal elements in a further tumour were positively stained with 21N antibody only. None of the second group of tumours, which included histological types known to have good prognosis, stained with 4D5, although one mucinous carcinoma was positively stained with 21N. These findings suggest that in invasive breast carcinoma immunostaining for c-erbB-2 is mainly seen in a subgroup of ductal tumours, and that almost all other histological types, especially those associated with good prognosis, lack this expression.
引用
收藏
页码:211 / 214
页数:4
相关论文
共 43 条
  • [11] IMMUNOHISTOCHEMICAL DISTRIBUTION OF C-ERBB-2 IN INFILTRATING AND INSITU BREAST-CANCER
    GUSTERSON, BA
    MACHIN, LG
    GULLICK, WJ
    GIBBS, NM
    POWLES, TJ
    PRICE, P
    MCKINNA, A
    HARRISON, S
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (06) : 842 - 845
  • [12] GUSTERSON BA, 1988, MOL CELL PROBE, V2, P383
  • [13] HEINTZ NH, 1990, ARCH PATHOL LAB MED, V114, P160
  • [14] P185HER2 MONOCLONAL-ANTIBODY HAS ANTIPROLIFERATIVE EFFECTS INVITRO AND SENSITIZES HUMAN-BREAST TUMOR-CELLS TO TUMOR NECROSIS FACTOR
    HUDZIAK, RM
    LEWIS, GD
    WINGET, M
    FENDLY, BM
    SHEPARD, HM
    ULLRICH, A
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (03) : 1165 - 1172
  • [15] AMPLIFIED EXPRESSION OF THE HER2/ERBB2 ONCOGENE INDUCES RESISTANCE TO TUMOR NECROSIS FACTOR-ALPHA IN NIH 3T3 CELLS
    HUDZIAK, RM
    LEWIS, GD
    SHALABY, MR
    EESSALU, TE
    AGGARWAL, BB
    ULLRICH, A
    SHEPARD, HM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (14) : 5102 - 5106
  • [16] INCREASED EXPRESSION OF THE PUTATIVE GROWTH-FACTOR RECEPTOR P185HER2 CAUSES TRANSFORMATION AND TUMORIGENESIS OF NIH-3T3 CELLS
    HUDZIAK, RM
    SCHLESSINGER, J
    ULLRICH, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (20) : 7159 - 7163
  • [17] C-ERBB-2 ONCOPROTEIN EXPRESSION IN MAMMARY AND EXTRAMAMMARY PAGETS-DISEASE - AN IMMUNOHISTOCHEMICAL STUDY
    KEATINGS, L
    SINCLAIR, J
    WRIGHT, C
    CORBETT, IP
    WATCHORN, C
    HENNESSY, C
    ANGUS, B
    LENNARD, T
    HORNE, CHW
    [J]. HISTOPATHOLOGY, 1990, 17 (03) : 243 - 247
  • [18] LAMMIE GA, 1989, HISTOPATHOLOGY, V15, P504
  • [19] C-ERBB2 EXPRESSION IN CORRELATION TO OTHER BIOLOGICAL PARAMETERS OF BREAST-CANCER
    MARX, D
    SCHAUER, A
    REICHE, C
    MAY, A
    UMMENHOFER, L
    RELES, A
    RAUSCHECKER, H
    SAUER, R
    SCHUMACHER, M
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1990, 116 (01) : 15 - 20
  • [20] MCDIVITT RW, 1968, ATLAS TUMOR PATHOL, P86